SEELQ — Seelos Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Guggenheim sees opportunities within neurology, immunology spaces in 2022
Brief: Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Seelos Therapeutics Files For Resale Of Up To 3.2 Million Shares
Brief: Seelos Therapeutics Announces Issuance Of Composition Of Matter Patent In Japan For SLS-007
U.S. STOCKS ON THE MOVE-Zoom, Gap Inc, Chevron
Seelos Therapuetics rises on drug licensing deal
Brief: Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
Brief: Seelos Therapeutics Raises $20 Mln In Private Placement Of Senior Secured Convertible Note
Brief: IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics
Seelos rises as FDA accepts clinical trial request for genetic disorder drug
Brief: Seelos Therapeutics Says FDA Accepts IND Application And Grants Fast Track Designation For Spinocerebellar Ataxia Treatment
Brief: Seelos Therapeutics Appoints Margaret Dalesandro To Board Of Directors
Brief: Seelos Therapeutics Announces Senior Management Appointments
Brief: Seelos Therapeutics Inc - As Of End Of Q2, Seelos Had $87.2 Mln Of Cash
Seelos Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Seelos rises on promising pre-clinical data on Parkinson's therapy
Brief: Seelos Therapeutics Announces Positive Data From Study For Parkinson's Disease Pathology
Brief: Seelos Therapeutics Doses First Patient In Part 2 Of A Registrational Study Of Sls-002 In Patients With Major Depressive Disorder
Brief: Seelos Added To The Russell 2000, Russell 3000 And Russell Microcap Indexes